Logo do repositório
 
Publicação

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

2024-02Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorLucena, M. I.
dc.contributor.authorVillanueva-Paz, M.
dc.contributor.authorAlvarez-Alvarez, I.
dc.contributor.authorAithal, G. P.
dc.contributor.authorBjörnsson, E. S.
dc.contributor.authorCakan-Akdogan, G.
dc.contributor.authorCubero, F. J.
dc.contributor.authorEsteves, F.
dc.contributor.authorFalcon-Perez, J. M.
dc.contributor.authorFromenty, B.
dc.contributor.authorGarcia-Ruiz, C.
dc.contributor.authorGrove, J. I.
dc.contributor.authorKonu, O.
dc.contributor.authorKranendonk, M.
dc.contributor.authorKullak-Ublick, G. A.
dc.contributor.authorMiranda, J. P.
dc.contributor.authorRemesal-Doblado, A.
dc.contributor.authorSancho-Bru, P.
dc.contributor.authorNelson, L.
dc.contributor.authorAndrade, R. J.
dc.contributor.authorDaly, A. K.
dc.contributor.authorFernandez-Checa, J. C.
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentre for Toxicogenomics and Human Health (ToxOmics)
dc.contributor.pblElsevier
dc.date.accessioned2024-02-19T23:47:52Z
dc.date.available2024-02-19T23:47:52Z
dc.date.issued2024-02
dc.descriptionFunding Information: The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu. Funding Information: The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21 ; PI21/01248 ; PI19/00883 ) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020 , Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02 , grant number 101095679 . Funded by the European Union . Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia ( FCT ). MVP and IAA hold Sara Borrell research contracts from ISCIII ( CD21/00198 and CD20/00083 , respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund . JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [ NIHR203310 ]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu . Publisher Copyright: © 2024 The Authors
dc.description.abstractIn the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1215381
dc.identifier.doi10.1016/j.phrs.2023.107046
dc.identifier.issn1043-6618
dc.identifier.otherPURE: 82960712
dc.identifier.otherPURE UUID: 4c4f4e72-f79e-43a5-a154-d95ba8da7193
dc.identifier.otherScopus: 85181835334
dc.identifier.otherPubMed: 38159783
dc.identifier.otherWOS: 001155023600001
dc.identifier.urihttp://hdl.handle.net/10362/163801
dc.identifier.urlhttps://www.scopus.com/pages/publications/85181835334
dc.language.isoeng
dc.peerreviewedyes
dc.subject3D culture
dc.subjectArtificial intelligence
dc.subjectAtypical DILI phenotypes
dc.subjectClinical trials
dc.subjectDILI prediction
dc.subjectDILI risk stratification
dc.subjectDrug safety
dc.subjectExtracellular vesicles
dc.subjectFamilial studies
dc.subjectHealth care
dc.subjectHumanized Mouse Models
dc.subjectIdiosyncratic Drug-induced liver injury
dc.subjectIntegrative database
dc.subjectIntegrative multi-scale data
dc.subjectNetworking
dc.subjectOrgan-on-a-chip
dc.subjectPharmacogenetic studies
dc.subjectPreclinical models
dc.subjectPrognostic biomarkers
dc.subjectRegulatory
dc.subjectZebrafish model
dc.subjectPharmacology
dc.titleRoadmap to DILI research in Europe. A proposal from COST action ProEuroDILINeten
dc.typejournal article
degois.publication.titlePharmacological Research
degois.publication.volume200
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1-s2.0-S1043661823004024-main.pdf
Tamanho:
1.16 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: ToxOmics - Artigos em revista internacional com arbitragem científica